Citation: Expert Opinion on Biological Therapy. , 2018 Jan 08.Journal: Expert opinion on biological therapy.Published: 2018ISSN: 1471-2598.Full author list: Evan JR; Bozkurt S; Thomas NC; Bagnato F.UI/PMID: 29309202.Subject(s): IN PROCESS -- NOT YET INDEXEDInstitution(s): MedStar Union Memorial HospitalActivity type: Journal Article.Medline article type(s): Journal ArticleDigital Object Identifier: https://dx.doi.org/10.1080/14712598.2018.1425388 (Click here)Abbreviated citation: Expert Opin Biol Ther. , 2018 Jan 08.Abstract: Introduction Alemtuzumab is a monoclonal antibody that targets for the destruction CD52+ cells, particularly B and T cells. Alemtuzumab is approved in more than 50 countries around the world for the treatment of adult patients with relapsing remitting multiple sclerosis (MS). Areas covered In this review, the authors summarize biological, clinical and safety data related to the use of alemtuzumab in patients with MS. The authors then provide their expert opinion on alemtuzumab and the field as of whole before providing their perspectives for the future. Expert opinion Alemtuzumab is highly efficacious; more so than first line treatments but comparable to natalizumab. Treatment schedule makes alemtuzumab administration easy and attractive to patients. However, its safety profile makes it a choice for a very limited number of patients, in a specific disease window. As of now, a cure for MS remains elusive and there is an unmet need for a safe and highly potent agent at the level of and beyond the blood brain barrier.